Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novozymes A/S    NZYM B   DK0060336014

NOVOZYMES A/S (NZYM B)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 08/16 03:37:39 pm
336.3 DKK   +0.99%
08/13NOVOZYMES A/S : Transactions under Novozymes’ stock buyback pr..
PU
08/10NOVOZYMES A/S : Interim report for the first half of 2018
AQ
08/10NOVOZYMES A/S : Half-year results
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novozymes A/S : Interim report for the first half of 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 01:58am EDT

Satisfactory first half with 4% organic sales growth

Organic sales growth of +4% in the first half (Q2: +5%): Household Care -1%, Food & Beverages +4%, Bioenergy +14%, Agriculture & Feed +3%, Technical & Pharma -6%. EBIT margin at 28.1%. FCF before acq. DKK 890 million. Net profit growth +5%. Full-year 2018 outlook maintained.

Peder Holk Nielsen, President & CEO of Novozymes: “Overall, I’m satisfied with our performance in the first half year. Bioenergy performed very well, whereas Household Care was softer than expected. Our innovation pipeline is solid, and a stronger commercial and emerging market focus is paying off. We’re launching a new, exciting product for animal health, and both our freshness & hygiene platform for laundry and the new corn inoculant are making good progress. And while uncertainty around global trade and agricultural markets persists, we remain committed to our 2018 guidance.”

Highlights 1H 2018:

  • Organic sales growth of +4% (Q2: +5%) and -4% in DKK. USD/DKK decline of 10% in 1H y/y
  • Organic sales growth of +4% (Q2: +5%) and -4% in DKK. USD/DKK decline of 10% in 1H y/y
  • Growth in Food & Beverages and Agriculture & Feed; Bioenergy particularly strong
  • Household Care softer than expected, as Q2 was impacted by customers’ region-specific challenges in Brazil and North America
  • +7% organic sales growth in emerging markets; developed markets +2%
  • Good ramp-up of recent product launches. Freshness & hygiene platform in Household Care developing according to plan with first commercial product available in stores in the Philippines. Preparation of BioAg’s B-360 corn inoculant in Q2 after regulatory approval in Q1
  • EBIT margin of 28.1% (1H 2017: 27.1%; 28.5% excluding reorganization costs) impacted by currency headwind, increasing input costs and lower deferred income
  • Net profit growth of +5% from lower financial costs and lower effective tax rate
  • Free cash flow before acquisitions at DKK 890 million; CAPEX at DKK 635 million

Full-year 2018 outlook maintained on all parameters: Organic sales growth of 4-6% with continuing high uncertainty around global trade and agricultural markets. Household Care still expected to grow organically for the full year, supported by the freshness & hygiene platform.


Attachment

  • 2018_47_Q22018_CompanyAnnouncement_FINAL_EN

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVOZYMES A/S
08/13NOVOZYMES A/S : Transactions under Novozymes’ stock buyback program
PU
08/10NOVOZYMES A/S : Interim report for the first half of 2018
AQ
08/10NOVOZYMES A/S : Half-year results
CO
08/07NOVOZYMES A/S : half-yearly earnings release
08/06NOVOZYMES A/S : Transactions under Novozymes’ stock buyback program
AQ
07/26NOVOZYMES A/S : Patent Issued for Detoxifying Pre-Treated Lignocellulose-Contain..
AQ
07/23NOVOZYMES A/S : Transactions under Novozymes’ stock buyback program
AQ
07/19NOVOZYMES A/S : Patent Issued for Epoxidation Using Peroxygenase (USPTO 10017483..
AQ
07/18NOVO NORDISK A/S : Vattenfall Signs New Offshore Wind Power Agreement
AQ
07/17NOVO NORDISK A/S : Vattenfall, Novozymes and Novo Nordisk sign a long term Power..
AQ
More news
News from SeekingAlpha
08/13Novozymes A/S 2018 Q2 - Results - Earnings Call Slides 
08/10Novozymes A/S (NVZMF) CEO Peder Nielsen on Q2 2018 Results - Earnings Call Tr.. 
08/10Novozymes A/S reports Q2 results 
06/22Treasure Hunting In The OTC Market 
06/18INTERNATIONAL FLAVORS & FRAGRANCES : That Taste In Your Mouth - Bitter Or Sweet? 
Financials (DKK)
Sales 2018 14 515 M
EBIT 2018 4 112 M
Net income 2018 3 236 M
Debt 2018 2 277 M
Yield 2018 1,50%
P/E ratio 2018 30,26
P/E ratio 2019 28,01
EV / Sales 2018 5,74x
EV / Sales 2019 5,45x
Capitalization 81 004 M
Chart NOVOZYMES A/S
Duration : Period :
Novozymes A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOZYMES A/S
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 318  DKK
Spread / Average Target -4,7%
EPS Revisions
Managers
NameTitle
Peder Holk Nielsen President & Chief Executive Officer
Jørgen Buhl Rasmussen Chairman
Thomas Videbaek COO, Executive VP-Research, Innovation & Supply
Prisca Havranek-Kosicek Chief Financial Officer & Executive Vice President
Carl Erik Mathias Uhlén Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVOZYMES A/S-6.06%12 384
SAUDI BASIC INDUSTRIES CORPORATION SJSC--.--%99 032
AIR LIQUIDE0.24%51 392
PRAXAIR0.43%44 672
LYONDELLBASELL INDUSTRIES0.40%43 441
SHIN-ETSU CHEMICAL CO LTD-9.91%41 377